Soboka Jibat Gemida, Giorgis Abeba T, Alemu Abiye M, Hodge W G, Damji Karim F
Department of Ophthalmology, College of Medical and Health Science, Haramaya University, Harar, Ethiopia.
Department of Ophthalmology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
J Ophthalmol. 2020 Sep 16;2020:7620706. doi: 10.1155/2020/7620706. eCollection 2020.
Selective laser trabeculoplasty (SLT) is a safe and effective treatment modality for lowering intraocular pressure (IOP).
To determine the efficacy and safety of SLT among Ethiopian patients with primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PXG), and ocular hypertension (OHT).
A prospective, nonrandomized interventional study was conducted at Menelik II Hospital, Ethiopia. Patients on antiglaucoma medication with uncontrolled IOP and those patients treated for the first time with 360 degrees of SLT were included. Success was defined as an IOP lowering of > 20% from baseline without repeat treatment.
A total of 95 eyes of 61 patients with a diagnosis of OAG and OHT were enrolled. The diagnosis was POAG in 55 (57.9%) eyes, PXG in 22 (23.2%) eyes, and OHT in 18 (18.9%) eyes. Seventy (73.7%) eyes were on medications, and 25 (26.3%) eyes were treated with laser as primary therapy. The mean (SD) baseline IOP and medication were 24.3 ± 2.5 mmHg and 1.29 ± 1.01, respectively. The one-year mean (SD) IOP reduction was 6.7 ± 4.2 mmHg and medication reduction was 0.26 ± 1.34. The overall IOP reduction at 12 months was 27.6%, and the success rate was 60%. The mean IOP (SD) reduction for patients who were treated for the first time with laser and on antiglaucoma medication was 6.5 ± 3.1 mmHg and 6.8 ± 2.8 mmHg, respectively. Post-SLT, patients experienced transient ocular pain, brow ache, headache, and/or blurring of vision in 31.6%, anterior chamber reaction in 36.8%, and IOP spike ≥ 6 mmHg in 11.6%.
SLT is an effective and safe treatment modality for OHT, POAG, and PXG among Ethiopian patients either as a first-line treatment or as an adjunct to topical glaucoma treatment.
选择性激光小梁成形术（SLT）是一种降低眼压（IOP）的安全有效的治疗方式。
确定SLT在埃塞俄比亚原发性开角型青光眼（POAG）、剥脱性青光眼（PXG）和高眼压症（OHT）患者中的疗效和安全性。
在埃塞俄比亚的梅内利克二世医院进行了一项前瞻性、非随机干预性研究。纳入了眼压控制不佳的青光眼药物治疗患者以及首次接受360度SLT治疗的患者。成功定义为眼压从基线降低>20%且无需重复治疗。
共纳入61例诊断为开角型青光眼和高眼压症患者的95只眼。诊断为POAG的有55只眼（57.9%），PXG的有22只眼（23.2%），OHT的有18只眼（18.9%）。70只眼（73.7%）正在使用药物治疗，25只眼（26.3%）接受激光作为初始治疗。平均（标准差）基线眼压和药物使用情况分别为24.3±2.5 mmHg和1.29±1.01。一年的平均（标准差）眼压降低为6.7±4.2 mmHg，药物使用减少为0.26±1.34。12个月时总体眼压降低为27.6%，成功率为60%。首次接受激光治疗且正在使用青光眼药物的患者，平均眼压（标准差）降低分别为6.5±3.1 mmHg和6.8±2.8 mmHg。SLT术后，31.6%的患者出现短暂眼痛、眉痛、头痛和/或视力模糊，36.8%的患者出现前房反应，11.6%的患者眼压升高≥6 mmHg。
对于埃塞俄比亚的高眼压症、原发性开角型青光眼和剥脱性青光眼患者，SLT作为一线治疗或局部青光眼治疗的辅助手段是一种有效且安全的治疗方式。
